Open AccessNivolumab + Relatlimab Continues Clinical Benefit in Advanced Melanoma
Author(s) -
Mark L. Fuerst
Publication year - 2022
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000830076.44871.db
Subject(s) - nivolumab , medicine , oncology , melanoma , clinical endpoint , ipilimumab , metastatic melanoma , progression free survival , clinical trial , immunotherapy , overall survival , cancer research , cancer